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Hashimoto's encephalopathyHashimoto's encephalopathy (HE) is an infrequent disease with no well-known physiopathology. Status
epilepticus is rarely reported in association with HE. We describe the 7-year evolution of a young woman
who presented with recurrent status epilepticus as the main complication of HE. This evolution was
especially marked by the occurrence of steroid-refractory symptoms and a poor outcome with persistent cog-
nitive and behavioral consequences.We point out that the frontal lobes are especially implicated in these symp-
toms. This patient highlights the risk of multiple relapses and the need for a long follow-up period. We
describe her clinical and paraclinical features, compare this patient to similar case reports, and comment
on her outcome.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-SA license.1. Introduction
“Hashimoto's encephalopathy” (HE), also called “steroid-responsive
encephalopathy associated with autoimmune thyroiditis” (SREAT), is a
rare condition that associates an encephalopathic state with an
autoimmune-mediated lymphocytic inﬁltration of the thyroid gland
(Hashimoto's thyroiditis, HT). The physiopathology of HE remains
unknown. A humoral autoimmune process is supported by the ﬁnding
of antineuronal [1] or anti-α-enolase antibodies [2]. Other anti-CNS
autoantibodies could be involved in the occurrence of HE, which might
explain the variability of the clinical features [1]. A vasculitic process is
not excluded in some patients, supported by stroke-like symptoms and
necrotic sequelae observed on brain MRI [3]. Although it is not certain
whether they have a true physiopathologic meaning, the high titer of
antithyroid antibodies leads to the diagnosis of HE, after exclusion of
other causes of encephalopathy. The prevalence of HE is estimated at
2.1/100,000 [4]. Since a large panel of unspeciﬁc neuropsychiatric symp-
toms can manifest during HE and before disclosing HT, its prevalence is
probably underestimated. Cognitive symptoms (as confusion, memory
loss, attention deﬁcit,…), psychiatric symptoms (as hallucinations, psy-
chosis, anxiety, agitation, jitteriness, …), alteration of consciousness,y, CHU-Brugmann, Place Van
37 60; fax: +32 2 477 34 67.
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nc.Open access under CC BY-NC-SA licseizure, tremor, ataxia, and stroke-like episodes can all be the
ﬁrst signs of the disease. Two clinical pictures were described by
Kothbauer-Margreiter et al., a diffuse progressive type and a
vasculitic type with stroke-like episodes [5]. Seizures are reported in
both andmore frequently in the diffuse type. Other authors reported sei-
zures in 66% ofHE, including status epilepticus (SE) in 12% [6]. Focal, gen-
eralized, myoclonic seizures and SE are described in associationwith HE.
As discussed by Ferlazzo et al., SE is generally resistant to antiepileptic
drugs (AEDs) andneeds steroids to improve [7]. To evaluate the outcome
of HE, only short series are reported. In a series of 20 patientswithHE [5],
steroid responsiveness is excellent in 90%, relapses following steroid
dose reduction occur in 40%, immunosuppressive drugs (ISDs) are used
in 10%, persistent cognitive symptoms remain in 15%, and uncontrolled
relapses persist in 10%. Concerning the issue of SE as a complication of
HE, only a few cases are reported in the literature with often a short
follow-up period, rendering their late outcome not well known.2. Case report
In 2006, a 26-year-old woman without relevant medical story
developed tremor, confusion, agitation, and blurred vision during a
few weeks. A ﬁrst episode of refractory generalized convulsive status
epilepticus (GCSE) followed and required anesthetic agents to im-
prove. A prolonged postictal status with bradypsychia, ataxia, and
tremor followed. The EEG was diffusely slowed. A slight right peri-
ventricular T2/FLAIR hyperintensity was observed on brain MRI. No
toxic, metabolic, or infectious etiologies were identiﬁed. She recov-
ered but promptly had a second episode of refractory GCSE despiteense.  
Table 1
Summary of neuropsychological test results.
March 2007 September 2011 April 2012
MOCA, global score [8] 15/30a
Spatiotemporal orientation 10/10 1/10a 3/10a
Episodic memory
– Free recall 42/64 [9] 0/4a [10] 0/4a [10]
– Cued recall 63/64 [9] 0/4a [10] 0/4a [10]
– Recognition 16/16 [9] 0/4a [10] 3/4 [10]
Short-term memory
– Digit span forward 4a 4a 3a
– Digit span backward 3a 4
Executive functions
– Trail Making Test A [11] 24 s
– Trail Making Test B [11] 48 s 1/1 [8]
– Frontal Assessment Battery [12] 8/18a 4/15ab
– Phonological verbal ﬂuency 19 5a [8] 8a
– Semantic verbal ﬂuency 21 9a
Visual attention test
– Bell Cancelation Test [13] 5 omissions, 0 false detections, 125 s Impaired 2 omissions, 16 false detections, 375 s
Visuospatial abilities
– Clock Drawing Test [8] 3/3 0/3a 2/3
a Pathological results with ≥2 standard deviation under the average.
b Incomplete test.
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period was prolonged anew with encephalopathy status. The EEG
was diffusely slowed with occasional right frontal rhythmic theta
activity. The brain Tc99m-bicisate SPECT reported right frontotemporal
hypoperfusion and a focal right paramedian frontal hyperperfusion.
A mild elevation of protein content without oligoclonal bands was
found in the cerebrospinal ﬂuid. The autoimmune screening in the
serum disclosed high titers of antithyroglobulin (274 IU/mL, normal b
60 IU/mL) and antithyroperoxidase (602.8 IU/mL, normal b60 IU/mL)
antibodies, with euthyroid status. Thyroid ultrasound was compatible
with thyroiditis status. Full body PET scan and CT scan did not reveal
neoplastic disease. Onconeural antibodies (anti-HU, anti-Yo, and anti-
Ri) were negative. The diagnosis of HE was probable. The EEG normal-
ized rapidly after intravenous methylprednisolone (1 g/day), and the
patient recovered. Phenytoinwas discontinued. At this stage, her cogni-
tive functions were almost normal with small deﬁcits for free recall
(episodic memory), selective attention, and verbal ﬂuency (Table 1).
Ten months later, steroids were progressively reduced because of side
effects (osteoporosis, Cushing-like syndrome, diabetes). A generalized
convulsive seizure relapsed rapidly. Phenytoin and steroids were
discontinued after six courses of cyclophosphamide. For 3 years, she
was free of treatment and seizures. Postural tremor, nervousness, and
anxiety persisted. In 2010, she presented a short collapse without
prolonged postictal status and a transient slowed EEG. Antiepileptic
drug was transiently used. In 2011, she relapsed into a GCSE resistant
to lormetazepam, phenytoin, levetiracetam, and intravenous methyl-
prednisolone. A burst-suppression state was obtained with thiopental.
For two months, it followed an encephalopathy state with subtle
SE of frontal origin. Plasmapheresis was performed. Different
antiepileptic drugs were used without success (phenytoin, pheno-
barbital, levetiracetam, lacosamide, and midazolam). The brain MRI
revealed T2 and FLAIR bilateral frontal hyperintensity spreading to
thalamic and mesiotemporal areas, without gadolinium enhancement
(Fig. 1). The brain PET scan showed bilateral frontal hyperactivity. The
EEG showed successively a drug-induced burst-suppression state, gen-
eralized periodic epileptiform discharges, a diffuse slowing with subtle
seizures of frontal origin, and a progressive return of alpha rhythm
(Fig. 2). Three months later, both EEG and brain MRI normalized.
Two years later, frontal behavior, memory loss, and loss of autonomy
persisted. The neuropsychological tests showed cognitive slowing,
poor spontaneous speech, apathy, poor orientation, episodic memo-
ry loss, perseverations, confabulations, and impairment of visuospa-
tial, attention, and executive functions (Table 1). Myoclonia andtransient loss of consciousness relapse under 8 mg a day of oral
methylprednisolone. In 2013, she continues to use chronically
antiepileptic drugs (levetiracetam, phenytoin, and phenobarbital)
and low dose of oral methylprednisolone.
3. Discussion and conclusion
We report the 7-year follow-up of a youngwomanwhopresentedwith
recurrent status epilepticus associated with Hashimoto's encephalopathy.
This diagnosis is sustained by high titer of antithyroid antibodies
and the exclusion of other toxic, metabolic, infectious, or
paraneoplastic etiologies. Through lack of typical features of
limbic encephalitis or N-methyl-D-aspartate receptor antibody
(NMDAR-Ab) encephalitis, a complete screening of antibodies
(Ab) against neuronal surface antigens (as voltage gate potassium
channel (VGKC) complex Ab, glutamic acid decarboxylase (GAD)
Ab, α-amino-3-hydroxy-5-methyl-4-isoxasolepropionic acid receptor
(AMPAR) Ab, and gamma-aminobutyric acid B receptor (GABAbR) Ab)
has not been performed.
Only a few cases of status epilepticus associated with HE have been
reported, and some are shown in Table 2. Including our cases, all present
the clinical diffuse progressive type of HE proposed by Kothbauer-
Margreiter et al. with ﬁrst symptoms equally distributed between thy-
roid dysfunction, behavioral changes, or SE. This distribution emphasizes
the clinical variability and the necessity to look for antithyroid Ab in the
case of SE of unknown origin.
Her evolution was ﬁrst characterized by a frontal EEG and SPECT
focalization in the course of a GCSE episode. Later, while spike–wave
discharges showed a diffuse spreading leading to an especially prolonged
NCSE, diffuse mesiotemporal and frontal postictal edema was observed
on the brain MRI. Seizures of frontal origin [14] or temporal origin
[15,16] have both been reported to be associated with HE. Among the
patients listed in Table 2 and using different diagnostic procedures
(brain MRI, PET scan, SPECT, or EEG), frontal dysfunction is more
frequently observed (6/10) than mesiotemporal dysfunction (1/10).
From a therapeutic point of view, her evolution was marked by
successive steroid responsiveness, steroid dependence, prolonged
remission after cyclophosphamide courses, late relapse of steroid-
resistant symptoms, and thereafter persisting steroid dependence.
No correlation could be made between the occurrence of steroid-
resistant symptoms and a delay in the beginning of intravenous
methylprednisolone. Steroid-resistant SE as a complication of HE
seems to be infrequent (2/11, including our patient and one patient
Fig. 1. T2 and FLAIR images show hyperintense lesions in bilateral frontal lobes and thalamic andmesiotemporal regions (better seen on coronal FLAIR images). T1-weighted images
show no contrast enhancement after gadolinium injection.
115H. Visée et al. / Epilepsy & Behavior Case Reports 1 (2013) 113–117in Table 2) but does not exclude the diagnosis. As reported by other
authors [5], a correlation has not been observed between relapses
and the level of antithyroid-Ab (Fig. 3), sustaining the hypothesis
that they do not play a part in the physiopathological development
of HE.
The outcomeofmost patients (8/11) listed in Table 2 is favorable but
has been commonly observed in a short follow-up period and often
with ongoing steroid or ISD use, making the conclusions debatable.
Early (2/11) and late (2/11) relapses following suspension of steroid
or ISD use are reported. One death occurred in the course of a
steroid-resistant SE. Two (including our patient) remain cognitively de-
ﬁcient as sequelae of prolonged steroid-resistant SE.
In conclusion, this case report emphasizes the possible frequent
relapses of SE as a complication of HE and the possible evolution to-
wards steroid-resistant SE. Clinicians should be aware that relapses
can occur early or even late after tapering of steroid or ISD use;
therefore, a long follow-up period should be advisable. Moreover,
since the antithyroid antibodies could not been used as markers ofencephalopathy's relapses, the question of the continuation of the
immunomodulatory of immunosuppressive drugs remains an open
debate.References
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Table 2
Ref Age, sex Type of
seizure
1st signs Brain MRI, SPECT/PET scan EEG Control
SE with
Follow-up
[17] 36, f CPSE CPSE MRI: left posterior frontal hypersignal Slow uk uk
[18] 61, f NCSE HD MRI: normal Generalized sharp and slow waves
discharges
S Remission at 2 W
[19] 79, f Focal seizure BC MRI: generalized atrophy, leukoaraiosis Diffuse or multifocal slowing AEDs Relapsed encephalopathy few M after
S, 4 M after ISDs, remission at 6 M with
ISDs and S
[20] 37, f Multifocal
motor SE
GTCS 1st MRI: normal
2nd MRI: hypersignal in both
precentral and left postcentral gyrus
Diffuse slowing, asynchronous
left or right central sharp waves
S Remission at 15 M with AEDs and ISDs
[21] 27, f GTCS, GCSE HD MRI: normal
SPECT: normal
Diffuse slowing, bifrontal theta
activity, photomyoclonia
AEDs Relapsed AEDs and S-resistant SE; death
[7] 41, m GCSE GCSE MRI: normal
SPECT: frontal hypoperfusion
Ictal: generalized epileptic activity
Postictal: slow, intermittent
frontotemporal bilateral slowing
S Remission at 1 Y with S, AEDs and HS
[9] 16, f GCS, CPSE BC MRI: right mediotemporal hypersignal
Ictal SPECT: right parietotemporal
hyperperfusion
Ictal EEG: rhythmic delta waves on
the right hemisphere
S Remission at 2 M
[22] 63, f GTCS, NCSE BD MRI: lacunar infarct
Pet scan: right frontal hypometabolism
Bilateral frontotemporal continuous
epileptic activity
AEDs Executive function impairment at 3 Y
[8] 51, f NCSE HD MRI: normal Bifrontal and generalized slow waves S Relapsed NCSE at 2 Y; Remission at
3 Y, with AEDs
[8] 66, m NCSE NCSE MRI: normal Bifrontal and generalized slow waves S Remission at 2 Y
AEDs, antiepileptic drugs; BC, behavioral changes; BD, Basedow's disease; CPSE, complex partial status epilepticus; GCS, generalized convulsive seizure; GCSE, generalized
convulsive status epilepticus; GTCS, generalized tonic–clonic seizure; HD, Hashimoto's disease; HS, hormonal substitution; ISDs, immunosuppresive drugs; M, months; NCSE,
nonconvulsive status epilepticus; S, steroids; SE, status epilepticus; uk, unknown; W, weeks; Y, years.
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